RE
HZNP

RBC Europe’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

RBC Europe’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,000
Closed -$19.5K – 1118
2018
Q4 		$19.5K Hold
1,000
– – ﹤0.01% 631
2018
Q3 		$19.6K Hold
1,000
– – ﹤0.01% 681
2018
Q2 		$16.6K Hold
1,000
– – ﹤0.01% 720
2018
Q1 		$14.2K Hold
1,000
– – ﹤0.01% 744
2017
Q4 		$14.6K Hold
1,000
– – ﹤0.01% 758
2017
Q3 		$12.7K Buy
+1,000
New +$12.7K ﹤0.01% 785

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RBC Europe's HZNP Position: Q1 2019 in Review

RBC Europe sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2019, closing a stake of 1,000 shares — an estimated $19.5K sold.

RBC Europe first reported a position in HZNP in Q3 2017 and held it in 6 quarters. The position peaked at $19.6K in Q3 2018. 297 funds tracked by Wall St. Rank hold HZNP as of Q1 2019.

  • RBC Europe reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2019 after selling out during the quarter.
  • RBC Europe sold 1,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2019, an estimated $19.5K.
  • RBC Europe first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2017 and held it in 6 quarters.
  • RBC Europe's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $19.6K in Q3 2018.
  • 297 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2019.

Based on RBC Europe's 13F filing for Q1 2019, filed 9 Nov 2023.